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ABSTRACT
The small GTPase RAB4 regulates endocytic
recycling, a process that contributes to Major
Histocompatibility Complex (MHC)-mediated anti-
gen presentation by specialized antigen presenting
cells (APC) of the immune system. The gene encod-
ing the RAB4B isoform of RAB4 was singled out by
two complementary genome-wide screens. One of
these consisted of a computer scan to identify
genes containing characteristic MHC class II-related
regulatory sequences. The second was the use of
chromatin immunoprecipitation coupled to microar-
rays (ChIP-on-chip) to identify novel targets of a
transcriptional co-activator called the MHC class II
transactivator (CIITA). We show that the RAB4B
gene is regulated by a typical MHC class II-like
enhancer that is controlled directly by both CIITA
and the multiprotein transcription factor complex
known as the MHC class II enhanceosome. RAB4B
expression is thus activated by the same regulatory
machinery that is known to be essential for the
expression of MHC class II genes. This molecular
link between the transcriptional activation of RAB4B
and MHC class II genes implies that APC boost their
antigen presentation capacity by increasing RAB4-
mediated endocytic recycling.
INTRODUCTION
The partitioning of eukaryotic cells into distinct compart-
ments by lipid membranes necessitates the existence of an
elaborate transport system capable of transferring membrane
components and cargos between different membrane-
bounded organelles and between these organelles and the
plasma membrane (PM). The various intracellular trafﬁcking
routes are served by specialized lipid vesicles that travel to
their destination along cytoskeleton ﬁlaments and fuse with
their target membranes by tightly regulated mechanisms. Pro-
teins belonging to the Rab family of small Ras-related
GTPases play pivotal roles in the regulation of intracellular
vesicular trafﬁc (1–3). Rab proteins associate with speciﬁc
vesicles and regulate multiple steps in their trafﬁcking, includ-
ing their formation and transport, cargo selection, as well as
docking to and fusion with their target membranes. To fulﬁll
these functions, Rab proteins are tightly regulated at the level
of their localization, membrane association, activation and
expression. The importance of the latter is underscored by
the fact that deregulated Rab expression is tightly correlated
with several pathologies, including vascular, lung and thyroid
disorders as well as a number of cancers (4,5).
Vesicular trafﬁc is of central importance for the presenta-
tion of peptides by Major Histocompatibility Complex
(MHC) molecules to the antigen receptors (TCRs) of T lym-
phocytes. MHC-mediated peptide presentation is essential for
the adaptive immune system because it governs the develop-
ment and activation of T cells. The engagement of MHC-
peptide complexes by the TCR of thymocytes during their
development in the thymus directs the positive and negative
selection processes that shape the mature T cell repertoire. In
the periphery, the recognition of peptides presented by MHC
molecules controls the initiation and development of T cell-
mediated immune responses directed against pathogens and
tumors. MHC-mediated peptide presentation is also critical
for the maintenance of tolerance to self-antigens and is impli-
cated in the breakdown of this self-tolerance during autoim-
mune diseases.
There are two classes of MHC molecules—MHC class I
(MHC-I) and MHC class II (MHC-II)—which differ with
respect to their pattern of expression, the nature of the pep-
tides they present, the T cell subsets that recognize them
and their functions in the immune system. MHC-I molecules
are expressed by all nucleated cells, and are specialized for
the presentation of peptides derived from the degradation of
intracellular proteins to the TCR of CD8+ T cells (6,7). Pep-
tides presented by MHC-I molecules are generated in the
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transporter (TAP) into the endoplasmic reticulum (ER),
where they are loaded onto newly synthesized MHC-I mole-
cules. The MHC-I-peptide complexes are then transported via
the golgi apparatus to the PM. MHC-II molecules are
expressed mainly by thymic epithelial cells and specialized
antigen presenting cells (APC; dendritic cells (DC), macro-
phages, B cells) and present peptides derived from extracellu-
lar proteins to the TCR of CD4+ T cells (7,8). These peptides
are generated in endocytic compartments by the proteolysis
of internalized proteins and are loaded onto MHC-II mole-
cules that have been transported into the endocytic compart-
ments thanks to their association with an accessory protein
called the invariant chain (Ii). Peptide-loaded MHC-II com-
plexes are then transported to the cell surface. The classical
MHC-I and MHC-II antigen presentation pathways depend
on vesicular transport routes that are regulated by well
known members of the Rab family.
In addition to the classical antigen presentation pathways,
there is growing evidence that endocytic recycling processes
play important roles in antigen presentation (9). The presenta-
tion of certain antigens requires the loading of peptides onto
MHC-II molecules that have been internalized by endocyto-
sis, followed by recycling of these peptide-MHC-II com-
plexes back to the cell surface (10–12). Such a recycling
pathway has notably been documented to be required for cer-
tain antigens taken up by receptor-mediated endocytosis in B
cells (13). Recycling of internalized cell surface MHC-I
molecules is also one of the mechanisms that allows peptides
derived from endocytosed proteins to be presented by MHC-I
molecules. This cross-presentation process is most efﬁcient in
DC (7,14,15). Finally, recent results have demonstrated that a
recycling pathway is involved in the presentation of intact
proteins by DC to the antigen receptors of B cells (16).
RAB4 is a key player in endocytic recycling. It is associ-
ated with early endosomes (EE) and recycling endosomes
(RE), and regulates the recycling of membranes and proteins
from these compartments back to the PM (1,17). There
are two highly homologous RAB4 isoforms—RAB4A and
RAB4B—encoded by two separate genes (RAB4A and
RAB4B). RAB4A and RAB4B are localized in the same
cellular compartments and are believed to have similar or
identical functions in recycling (18,19). Importantly, RAB4
has been implicated directly in MHC-II-restricted antigen
presentation; a dominant negative mutant of RAB4 was
shown to block the presentation of antigens internalized by
receptor-mediated uptake in B cells (13).
We show here that transcription of the RAB4B gene is
controlled by the same regulatory machinery that is critical
for the expression of MHC-II genes and enhances the exp-
ression of MHC-I genes. The promoter of RAB4B contains
a strongly conserved enhancer known as the S-Y module,
which was until now believed to be highly speciﬁc for
MHC-II and related genes. This RAB4B S-Y module is regu-
lated by the same transcription factors that are dedicated for
the activation of MHC-II expression. These notably include
the transcription factor called Regulatory Factor X (RFX)
and a transcriptional co-activator known as the MHC class
II transactivator (CIITA). This molecular link between the
transcriptional activation of RAB4B and genes involved in
antigen presentation implies that APC boost their antigen
presentation capacity by increasing the efﬁciency of endo-
cytic recycling.
MATERIALS AND METHODS
Identification of the RAB4B S-Y module
The generation of proﬁles used to search for S-Y sequences
has been described (20). The proﬁle used here is provided
in Supplementary Figure 1A. Scans of the human Genomic
Reference Sequence, build 29 (International Human Genome
Sequencing Consortium), were performed with the program
pfscan from the pftools package (available at ftp://ftp.isrec.
isb-sib.ch/pub/software/unix/pftools/) which is a software
implementation of the generalized proﬁle method (21).
Cells
RJ2.2.5 B cells (22,23), SJO B cells (24), SJO cells comple-
mented with RFX5 (25), RJ2.2.5 cells complemented as
described (25,26) with lentiviral vectors encoding CIITA
isoforms I, III or IV and Me67.8 melanoma cells (27) were
grown in RPMI+Glutamax medium (Invitrogen) supple-
mented with 10% fetal calf serum and antibiotics. Me67.8
cells were induced with 200 U/ml of IFN-g (Invitrogen).
HUVEC were prepared as described (28) and induced with
1000 U/ml of IFN-g (Invitrogen). Human monocyte-derived
DC were prepared, matured with LPS and analyzed by
FACS as described (29).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described using rabbit RFX, CREB
and CIITA antisera (20,30). Results were quantiﬁed by
real-time PCR as described (20) using the primers listed in
Supplementary Table 1A. All results are presented as the
mean ± SD of at least two independent ChIP experiments
and three independent ampliﬁcations.
ChIP-on-chip experiments
The quality of CIITA-ChIP samples was veriﬁed by assessing
the enrichment of HLA–DRA sequences. Under our condi-
tions, the CIITA antibody precipitates  2% of the input
HLA–DRA promoter fragments but <0.01% of non-speciﬁc
DNA. DNA extracted from CIITA-ChIP samples were
blunted for 30 min at 72 C with 3 U of Pfu polymerase
(Promega) and phosphorylated with T4 Polynucleotide kinase
(New England Biolabs). 120 pmoles of adaptors consisting of
annealed oligonucleotides A (50-GCGGTGACCCGGGAGA-
TCTGAATTC-30) and B (50-GAATTCAGATC-30) were
ligated to the DNA by overnight incubation at 16 C with
2000 U of T4 DNA ligase (New England Biolabs). Two
rounds of PCR ampliﬁcation with oligonucleotide A were
performed using 1.25 U of Taq polymerase (New England
Biolabs) and 0.025 U of Pfu Turbo polymerase (Stratagene).
The cycle used was: 1 · (20 at 55 C, 50 at 72 C, 20 at 95 C),
28 · (10 at 95 C, 10 at 60 C, 20 at 72 C), 50 at 72 C. Four
micrograms of each DNA were puriﬁed and sent to Nimble-
Gen Inc for probe preparation and hybridization. The arrays
were either the NimbleGen 5 kb human promoter array set
or a custom array of our own design carrying selected regions
of human genomic DNA. Genomic sequences on the custom
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TM-matched oligonucleotides ( 50 bp long) spaced such
that their 50 ends are situated  10 bp apart. Each comparison
between CIITA-ChIP and control probes was repeated at least
twice.
Plasmids and reporter gene assays
The complete and minimal HLA–DRA luciferase constructs
have been described (30). Plasmids containing the RAB4B
S-Y and RAB4B Y-S sequences were created by replacing
the MluI-BglII fragment spanning the S-Y region of
HLA–DRA with the PCR fragments containing the RAB4B
S-Y motif. Primers used to generate these constructs are
listed in Supplementary Table 1B. Mutations were introduced
into the RAB4B S-Y module by site-directed mutagenesis.
Luciferase reporter gene assays were done as described
(20). The results are presented as the mean ± SD of three
assays.
mRNA quantification
RNA extraction, cDNA synthesis and real-time PCR were
done as described (30). TBP mRNA was used for normaliza-
tion. The results are presented as the mean ± SD of three
independent quantiﬁcations. Primer sequences are listed in
Supplementary Table 1C.
RESULTS
A typical MHC-II-like S-Y module is found upstream
of the RAB4B gene
In man there are three classical MHC-II isotypes—HLA–DR,
HLA–DP and HLA–DQ—each of which is a heterodimer
consisting of an a chain and a b chain. There are also two
non-classical MHC-II heterodimers—HLA–DO and HLA–
DM—playing intracellular roles in peptide loading of the
classical MHC-II molecules. The genes encoding the a and
b chains of all classical and non-classical MHC-II isotypes,
as well as the gene encoding the MHC-II-associated invariant
chain (Ii), are tightly co-regulated by a highly conserved
regulatory element called the S-X-X2-Y (S-Y) module, which
is located near to the transcription initiation site of each gene
(Figure 1A) (31,32). Similar S-Y sequences also contribute,
albeit to a lesser degree, to the expression of MHC-I
genes (33).
The X, X2, Y and S sequences in the S-Y module are
bound, respectively, by RFX, cAMP response element bind-
ing protein (CREB), nuclear factor Y (NF-Y) and an as yet
unidentiﬁed S-binding factor (Figure 1A) (24,34–39). These
transcription factors bind cooperatively to the S-Y module
to form a multiprotein complex called the MHC-II enhanceo-
some, which constitutes a platform to which a transcriptional
co-activator called the class II transactivator (CIITA) is
recruited (Figure 1A) (40,41). CIITA coordinates most of
the processes that are required to activate the transcription
of MHC-II genes, including chromatin remodeling, recruit-
ment of the general transcription machinery (GTM), promoter
clearance by RNA polymerase II and transcription elongation
(42,43).
The S-Y module is strictly conserved with respect to the
sequence, orientation, position and spacing of its four subele-
ments (31,32). This unique architecture allowed us to gener-
ate a stringent sequence proﬁle that can be used to predict the
presence of novel S-Y like sequences with a high degree of
conﬁdence. We previously validated this approach by identi-
fying novel S-Y enhancers in the Ii gene and within the
MHC-II locus (20). The sequence information derived from
these new S-Y modules was incorporated into a new proﬁle
Figure 1. Identification of an S-Y module in the upstream region of the
RAB4B gene. (A) Schematic drawing of the regulatory machinery controlling
the transcription of MHC-II genes. The promoters of all MHC-II genes
contain a conserved regulatory module (S-X-X2-Y) that is recognized by an
enhanceosome complex consisting of RFX, CREB and NF-Y. Transcription
is activated by recruitment of the co-activator CIITA to this enhanceosome.
(B) The 3 kb upstream regions of all human genes were scanned with the
MHC-II S-Y profile. Sequences bearing similarity to S-Y modules are plotted
with respect to their position in the genome and the score attributed by the
search algorithm. S-Y sequences in the RAB4B, invariant chain (Ii) and
MHC-II genes are indicated. (C) Alignment between the human HLA–DRA
S-Y module and the S-Y sequences found in the RAB4B genes of the
indicated organisms. The most conserved residues are highlighted. A
sequence logo representing the consensus MHC-II S-Y motif is shown
below; the font size reflects the frequency at which a nucleotide is found at a
given position. (D) Sequence conservation in the intergenic region between
the RAB4B and MIA genes is represented by a graph derived from the
Conservation track available at the UCSC Genome Browser at genome.ucsc.
edu. The track shows a measure of the evolutionary conservation between
17 vertebrates. A peak corresponding to the most strongly conserved
sequence in the intergenic region overlaps with the X–X2 region of the S-Y
module.
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the search algorithm and the in vivo binding efﬁciency of
CIITA and RFX (20).
We have used the improved proﬁle to search for new S-Y
modules in the 3 kb upstream regions of all human genes
(Figure 1B). Outside of the MHC locus and Ii gene, the
scan detected only 21 matches with scores greater than
a value of 10. This threshold was chosen on the basis of
the scores obtained for known bona ﬁde target sequences of
RFX and CIITA (20). Most of the 21 candidates were
assigned relatively low scores (10 to 12). However, a putative
S-Y module having a high score (17.3) was identiﬁed 625 bp
upstream of the predicted transcription initiation site of the
human RAB4B gene (Figure 1B).
The RAB4B S-Y motif exhibits strong resemblance to
the S-Y sequences of MHC-II genes, as demonstrated by its
alignment with the S-Y module of the prototypical HLA–
DRA gene (Figure 1C). As observed when S-Y modules
from different MHC-II genes are aligned, similarity between
the RAB4B and HLA–DRA S-Y motifs is greatest in the core
X and Y sequences. The RAB4B S-Y motif is highly
conserved in the orthologous genes of other vertebrates
(Figure 1C). In fact, sequence conservation between the
upstream regions of vertebrate RAB4B genes is strongest at
a position that coincides with the X-X2 sequence of the
S-Y module (Figure 1D). This conservation is as strong as
that of the core-promoter situated near the transcription
start site.
The RAB4B S-Y module is a direct target of CIITA
As a second approach for identifying new target genes regu-
lated by the MHC-II regulatory machinery we used a ChIP-
on-chip method relying on the use of microarrays (chip) to
analyze the results of ChIP experiments (44). DNAs extracted
from ChIP samples obtained with a CIITA-speciﬁc antiserum
were used to prepare probes that were hybridized to mirco-
arrays carrying genomic sequences. Two types of arrays
were used. The ﬁrst was the human 5 kb promoter array set
from NimbleGen Inc. which carries 5 kb promoter regions
( 4k bt o+1 kb relative to transcription start site) of
27434 human genes. The second was a high density array
of our own design carrying selected genomic regions relevant
to the regulation of MHC-II gene expression.
CIITA-ChIP samples were prepared from two different
CIITA-positive cell types, a wild-type human B cell line
(Raji) and human monocyte-derived DC. Hybridization sig-
nals obtained with these CIITA-ChIP probes were compared
with those obtained with control probes. As controls for the
B cell experiments we used genomic DNA or CIITA-ChIP
samples prepared from a CIITA-deﬁcient mutant of Raji
(RJ2.2.5). As controls for the DC experiments we used
CIITA-ChIP samples prepared from DC in which maturation
had been induced by treatment with LPS for 24 h. Maturation
of DC induces rapid silencing of the CIITA gene (45).
The ChIP-on-chip experiments revealed that CIITA binds
efﬁciently to the upstream region of the RAB4B gene in B
cells (Figure 2A) and immature DC (Figure 3A). The signals
obtained for binding of CIITA coincide with the RAB4B S-Y
module identiﬁed by the computer search. Speciﬁcity is
demonstrated by the absence of signals in the upstream region
of the closely related RAB4A gene, which does not contain
an S-Y module (Figures 2B and 3B). The signals obtained
for the RAB4B S-Y module are similar in strength to those
observed for the typical S-Y modules found upstream of
Figure 2. Binding of CIITA to the RAB4B promoter region in B cells.
Binding of CIITA to the RAB4B (A), RAB4A (B) and HLA–DRA, HLA–DPA
and HLA–DPB (C) promoter regions was assessed by ChIP-on-chip
experiments. The results are represented as log2 ratios between the
hybridization signals obtained for CIITA-ChIP DNAs derived from CIITA-
positive B cells (wt) and those obtained with control DNAs. Controls were
CIITA-ChIP DNAs from CIITA-/- B cells or input genomic DNA. Arrays
were either the standard NimbleGen promoter arrays or a high density custom
array. Each bar corresponds to a single oligonucleotide on the array. Grey
bars correspond to log2 ratios lower than zero and reflect stronger signals for
the control samples. The latter probably result from sporadic random
amplification of short DNA fragments in the control samples. Schematic
maps with positions of the genes (open boxes), transcription start sites
(arrows) and S-Y modules (grey boxes) are shown.
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and 3C). The strength of the signals observed at RAB4B are
well within the range of those obtained for the S-Y modules
of other classical MHC-II genes, the non-classical HLA–DM
and HLA–DO genes, and the Ii gene (Table 1).
The signals obtained for binding of CIITA in ChIP-on-chip
and classical ChIP experiments vary substantially between
the different promoter-proximal and -distal S-Y modules
(Table 1). This variability is likely to reﬂect a combination
of differences in multiple parameters, including enhanceo-
some stability, efﬁciency of CIITA recruitment, cell-type
speciﬁc expression patterns, accessibility of the epitopes rec-
ognized by the antibodies and crosslinking efﬁciency.
In addition to RAB4B, the ChIP-on-chip experiments
identiﬁed a relatively small number (>40) of other loci
containing potential CIITA binding sites. None of these cor-
respond to genes proposed previously to be targets of CIITA.
As done here for RAB4B, these potential new target genes
will have to be validated by classical ChIP experiments and
expression studies comparing wild-type and CIITA-deﬁcient
cells.
RAB4B expression is regulated by CIITA
CIITA is called the master regulator of MHC-II genes
because its pattern of expression dictates the cell-type
speciﬁcity and level of MHC-II expression (32,42,46). APC
such as B cells are MHC-II positive because they express
CIITA constitutively. Most cells of non-hematopoietic origin
do not express CIITA and are consequently MHC-II negative.
However, the latter can generally be induced to express
MHC-II genes by stimulation with interferon g (IFN-g),
which activates the expression of CIITA.
To determine whether RAB4B is regulated by CIITA in B
cells we quantiﬁed RAB4B mRNA levels by real-time
RT–PCR in the Raji B cell line, its isogenic CIITA-deﬁcient
mutant RJ2.2.5 and RJ2.2.5 cells complemented by transfec-
tion with CIITA expression vectors. Expression of RAB4B
mRNA was reduced 3-4 fold in RJ.2.2.5 cells but was
restored to levels exceeding those observed in wild-type
Raji cells by complementation of the RJ2.2.5 cells with
CIITA expression vectors (Figure 4A). All three isoforms
of CIITA (isoforms I, III and IV) restored RAB4B expression.
The dependence of RAB4B expression on CIITA is very simi-
lar to that observed for the HLA–DRA gene (Figure 4A). The
only notable difference is that a basal level of RAB4B mRNA
is retained in RJ2.2.5 whereas HLA–DRA expression is com-
pletely lost in these cells. This is reminiscent of human
MHC-I genes, which also show only partially reduced expres-
sion in CIITA-deﬁcient cells.
To determine whether RAB4B expression is induced
by IFN-g, we performed real-time RT–PCR experiments
with a human melanoma cell line (Figure 4B) and
primary human umbilical vein endothelial cells (HUVEC,
Figure 4C). In both cell types, RAB4B mRNA expression is
increased 4–5 fold by IFN-g according to a time course that
is very similar to the one observed for the robust induction of
HLA–DRA mRNA. The major difference between the two
induction patterns is that there is a basal level of RAB4B
but not HLA–DRA mRNA in non-induced cells. This is
again similar to MHC-I genes, which are expressed at a
basal level in most cell types in the absence of IFN-g induced
CIITA expression.
No signiﬁcant amount of RAB4A mRNA was detected
in either Raji or RJ2.2.5 cells (Figure 4A). Further-
more, no increase in RAB4A mRNA abundance was observed
in IFN-g induced cells (Figure 4B and C). This is consis-
tent with the fact that the RAB4A gene does not contain
an S-Y module and is not bound by CIITA (Figures 2B
and 3B). Regulation by CIITA is thus speciﬁc for the
RAB4B gene.
We also analyzed expression of the MIA gene, which is
located close to RAB4B (see Figures 1–3). MIA mRNA levels
were negligibly low (>1000-fold less than RAB4B) in B cells
(data not shown). Moreover, no signiﬁcant basal or IFN-g
induced MIA expression was observed in HUVEC (data not
shown). The MIA gene is thus not active in cells that express
CIITA and is therefore not likely to be a target of the MHC-II
regulatory machinery.
Enhanceosome assembly and CIITA recruitment
at the RAB4B S-Y module
CIITA is recruited to the promoters of MHC-II genes by
protein–protein interactions with the enhanceosome complex
that assembles at their S-Y modules. To determine whether
the MHC-II enhanceosome also assembles at the RAB4B
Figure 3. (A–C) Binding of CIITA to the RAB4B promoter region in DC.
Binding of CIITA in immature DC (iDC) was assessed by ChIP-on-chip
experiments as in Figure 2. The control hybridization was done with CIITA-
ChIP DNA from mature DC (mDC).
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ies directed against CIITA, RFX and CREB. All three factors
associate with the RAB4B promoter in Raji B cells
(Figure 5A). Occupation of the RAB4B promoter relative to
the HLA–DRA promoter ranged from  20% for CIITA to
 70% for CREB. Although lower, this occupation remains
well within the range observed for known MHC-II genes,
which is (as discussed above for CIITA) quite variable
(Table 1). Speciﬁcity is demonstrated by the absence of
detectable binding of the three factors to the promoter of
the control TATA-binding protein (TBP) gene.
RFX is a hetero-trimeric factor consisting of RFX5, RFX
associated protein (RFXAP) and RFX associated protein
containing ankyrin repeats (RFXANK) (24,34–36). Mutations
in any one of these three subunits abolish binding of the RFX
complex, and thus eliminate both enhanceosome assembly
and CIITA recruitment at the S-Y modules of MHC-II
genes (Figure 5C) (30,41). Conversely, mutations in CIITA
do not abrogate binding of RFX and enhanceosome assembly
(Figure 5C) (30). A similar pattern is observed at the RAB4B
S-Y module. Binding of CIITA and RFX5 are completely
lost in RFX5-deﬁcient SJO cells. This is revealed by classical
ChIP experiments using antibodies against CIITA and RFX5
(Figure 5B) and ChIP-on-chip experiments comparing bind-
ing of CIITA in wild-type and SJO cells (Figure 5D). On
the other hand, RFX5 and CREB bind normally to the
RAB4B S-Y module in CIITA-deﬁcient B cells, indicating
that enhanceosome assembly is independent of CIITA
(Figure 5B). These results indicate that assembly of the
enhanceosome and recruitment of CIITA at the RAB4B pro-
moter follows the same rules as those previously established
for MHC-II genes.
RAB4B promoter occupancy by RFX and CIITA
in DC and IFN-g induced cells
The maturation of DC is accompanied by rapid silencing
of the CIITA gene. Binding of CIITA to the HLA–DRA pro-
moter in ChIP experiments is consequently strongly reduced
in DC that have been induced to mature by exposure to LPS
(Figure 6A). This reduction is also evident at the RAB4B
promoter, where the occupancy by CIITA is reduced more
than 10-fold during DC maturation (Figure 6A).
Binding of CIITA to the RAB4B promoter was also
assessed in IFN-g induced melanoma cells (Figure 6B and C).
IFN-g induced occupancy of the RAB4B promoter by CIITA
follows a time course that is identical to that observed for the
HLA–DRA promoter. Binding is not detected prior to induc-
tion, ﬁrst becomes evident after 4 h and reaches a plateau by
6 h (Figure 6B). At the HLA–DRA promoter, stability of
the enhanceosome is enhanced by CIITA in IFN-g induced
cells. This manifests itself in ChIP experiments by a 2–3
fold increase in the signals obtained for binding of RFX5
(Figure 6C). A similar increase in RFX occupancy is detected
at the RAB4B promoter (Figure 6C). The time course of the
IFN-g induced increase in RFX binding at the RAB4B
promoter closely parallels that observed at the HLA–DRA
promoter.
The RAB4B S-Y module functions as a CIITA
and RFX-dependent enhancer
To conﬁrm that the RAB4B S-Y module functions as an RFX-
and CIITA-dependent enhancer we performed luciferase
reporter gene assays using a strategy that was ﬁrst devised
to validate the novel S-Y enhancers discovered in the
Table 1. Scores assigned by the profile search and binding of RFX and CIITA to S-Y modules
S-Y module



















e —5 9 4 05 7
DRB1 18.73 — — 81 45 57
DRA 18.15 100 100 100 100 100
DRAe 17.91 50 30 47 61 38
DQB 17.44 — — 34 11 41
RAB4B 17.33 47 22 48 52 69
DPA 17.27 103 79 29 62 19
#4 17.02 59 49 28 31 33
Ii 15.02 41 33 32 33 54
DOB 14.65 — 4 44 27 79
DMA 14.63 — — 61 49 62
DPB 14.07 41 13 28 80 40
DOA 13.57 — 15 30 19 29
#8 13.24 103 108 — — 27
DMB 13.02 14 7 43 40 46
#2 12.59 93 92 — — 47
Ii S0-Y0 12.45 80 19 — — 28
DQA 11.18 — 3 19 18 1
Ii Y00-S00 10.42 19 6 — — 33
#6 9.33 52 16 — — 42
aS-Ymodulesfoundin the promoter-proximalregionsof the indicatedMHC-IIgenes, or in distal enhancers(DRAe, Ii S0-Y0, Ii Y00-S00,#2, #4, #6 and #8)described
previously (20,30).
bin B cells, relative to DRA (set at 100%).
cvalues were calculated as peak surfaces (peak length multiplied by the average intensity obtained for separate probes) and represented relative to DRA (set
at 100%).
dHD, high density array.
e—, not done (ChIP) or not on array (ChIP-on-chip).
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gene constructs in which the S-Y module of the HLA–DRA
promoter was replaced with the RAB4B S-Y module in the
forward (S-Y) or reverse (Y-S) orientation (Figure 7A).
These two RAB4B constructs, the HLA–DRA construct and
a control construct driven by a minimal DRA promoter
lacking an S-Y module were transfected into ﬁve cell types;
wild-type Raji B cells, CIITA-deﬁcient RJ2.2.5 cells, RFX5-
deﬁcient SJO cells, RJ2.2.5 cells corrected by complementa-
tion with CIITA and SJO cells corrected by complementation
with RFX5 (Figure 7A). In wild- type Raji cells, the RAB4B
S-Y and Y-S constructs attained activities exceeding 50 and
30%, respectively, of that observed for the HLA–DRA con-
struct. Although lower than for HLA–DRA, these levels
were nevertheless 30-fold greater than the basal activity of
the minimal promoter construct. Both RAB4B constructs
exhibited a pattern of activity in the different cell types that
was very similar to that observed for the HLA–DRA construct.
The strong expression observed in wild-type B cells was
Figure 5. Occupation of the RAB4B promoter by the MHC-II specific
regulatory machinery. (A) The association of CIITA, RFX5 and CREB with
the HLA–DRA, RAB4B and TBP promoters was assessed by ChIP in wt B
cells. Results are expressed as % of occupation observed at the HLA-DRA
promoter. (B) Occupancy of the RAB4B promoter by CIITA, RFX5 and
CREB was analyzed in wt B cells and in mutant B cells lacking CIITA or
RFX5. Results are expressed as % of the occupation observed in the wt cells.
(C) Occupancy of the HLA–DRA promoter was analyzed as in (B).
(D) Binding of CIITA to the RAB4B promoter was analyzed by ChIP-on-
chip. Results are represented as ratios between the signals obtained with
CIITA-ChIP DNAs from wt and CIITA-/- B cells (top) or wt and RFX5-/- B
cells (bottom). N.D., not done.
Figure 4. Expression of RAB4B is controlled by CIITA and is induced by
IFN-g. mRNA levels for the RAB4B, HLA-DRA and RAB4A genes were
determined for (A) wt B cells (Raji), CIITA-/- B cells (RJ2.2.5) and CIITA-/-
cells complemented with expression vectors encoding the three isoforms of
CIITA (CIITA I, III and IV), (B) Me67.8 melanoma cells (Me) induced with
IFN-g for 0, 12, 24 and 48 h and (C) HUVEC cells induced with IFN-g for 0,
12, 24 and 48 h. Results were normalized using TBP mRNA. Values for
RAB4B and RAB4A are expressed as % of the levels found in wt B cells (A)o r
relative to uninduced cells (B and C). Values for HLA–DRA mRNA are
expressed as % of the levels found in wt B cells (A) or cells induced with
IFN-g for 48 h (B and C).
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CIITA or RFX. This loss in expression was restored by
re-introducing CIITA or RFX in the corresponding mutant
cells. Taken together, these results indicate that the RAB4B
S-Y module functions as transcriptional enhancer regulated
by RFX and CIITA.
To conﬁrm that the RAB4B S-Y module functions as a
typical S-Y enhancer we performed reporter gene assays
with constructs carrying mutations in its S, X, X2 or Y
sequences (Figure 7B). The mutations were chosen on the
basis of their previously documented ability to affect activity
of the HLA–DRA S-Y module and to interfere with assembly
of the enhanceosome complex. All four mutations decreased
activity of the RAB4B construct in Raji cells (Figure 7B). The
X mutation abrogated activity completely, underscoring the
pivotal importance of the RFX target sequence. The Y, S
and X2 box mutations decreased activity by approximately
70%, 40% and 30%, respectively. The remaining activities
of the mutated Y, S and X2 constructs were eliminated in
CIITA-deﬁcient cells and must thus result from partial
CIITA recruitment. These results are in full agreement with
previous studies on MHC-II promoters, which have demon-
strated that destruction of the X box is always extremely
detrimental whereas mutations in the S, X2 and Y motifs gen-
erally inhibit promoter function only partially (39,47).
DISCUSSION
We have used two strategies to identify genes that are
co-regulated with MHC-II genes. First, we used a computer
scan to search for genes that contain MHC-II-like S-Y
enhancers in their upstream regions. Second, we performed
ChIP-on-chip screens to identify genes that are direct targets
of CIITA, the master regulator of MHC-II genes. These two
approaches have converged on RAB4B, a gene encoding a
protein implicated in endosome recycling. A combination
of ChIP, ChIP-on-chip, expression analysis and functional
studies in wild-type and mutant cells lacking CIITA or
RFX have conﬁrmed that RAB4B expression is indeed driven
by a typical S-Y enhancer that is regulated by both CIITA
and the MHC-II enhanceosome complex composed of RFX,
CREB and NF-Y.
Searching for potential binding sites in genomic DNA
sequences is generally of limited usefulness for identifying
target genes regulated by speciﬁc transcription factors. A
major problem with such approaches is that transcription fac-
tor binding sites are often short and degenerate with respect
to their consensus sequence, such that computer searches
for potential binding sites tend to yield overwhelmingly
large numbers of irrelevant hits. Our searches with the
MHC-II S-Y proﬁle constitute an exception to this rule
because they have proved to be remarkably reliable—in this
report and in a previous study (20)—for the identiﬁcation of
novel enhancers regulated by the MHC-II enhanceosome
complex and CIITA. The success of our approach implies
that similar strategies could be valuable for identifying genes
regulated by higher order transcription factor complexes, par-
ticularly in systems where gene expression is controlled by
well-deﬁned composite regulatory modules.
The use of genome-scale ChIP-on-chip-based binding stud-
ies to identify target genes of speciﬁc transcription factors in
eukaryotic organisms has become feasible only recently
thanks to the availability of microarrays covering entire gen-
omes, large genomic regions or the promoter regions of com-
prehensive sets of genes. To date, ChIP-on-chip studies have
investigated the target gene speciﬁcity of DNA-binding tran-
scription factors (48–52). We demonstrate here that such
ChIP-on-chip experiments can also be very powerful for
Figure 6. Occupation of the RAB4B promoter by the MHC-II regulatory
machinery in DC and IFN-g induced cells. (A) Binding of CIITA to the
RAB4B, HLA-DRA and TBP promoters was analyzed by ChIP in DC before
(iDC) and after (mDC) maturation with LPS. Results are represented as % of
the occupation observed at the HLA-DRA promoter in iDC. The TBP
promoter was used as a negative control. (B and C) ChIP was used to measure
occupancy of the RAB4B promoter by CIITA (B) and RFX5 (C) in Me67.8
melanoma cells induced with IFN-g for 0, 2, 4, 6 and 12 h. Results are
represented as % of the occupation observed at the HLA–DRA promoter after
12 h of induction.
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co-activators such as CIITA.
Past efforts to identify new genes regulated by CIITA have
led to a certain amount of controversy concerning the target
gene speciﬁcity of CIITA (53). CIITA was initially believed
to be dedicated for the expression of classical MHC-II genes
and related genes implicated in antigen presentation,
including the Ii, HLA–DO, HLA–DM and MHC-I genes.
Subsequent reports suggested that CIITA might be more
pleiotropic in its function. Several genes were suggested to
be repressed by CIITA in various cell types, including
those encoding IL4 and FasL in T cells, cathepsin E and
IL-10 in B cells and DC, and collagen type I a2, thymidine
kinase and cyclin D1 in IFN-g induced cells (54–57). A
microarray experiment suggested that at least 16 other
genes of diverse functions are repressed by CIITA in a
human B cell line (58). Finally, microarray experiments
have suggested that CIITA enhances the expression of
Plexin-A1 in mouse DC and numerous other genes, including
RAB4B, in a human B cell line and in IFN-g induced cells
(58,59). However, none of these candidate genes have as
yet been demonstrated to be controlled by S-Y enhancers or
been validated as direct targets of the MHC-II regulatory
machinery by ChIP experiments. In fact, for several candi-
dates an indirect mechanism involving sequestration of
the general co-activator CBP by CIITA has been proposed
(54–57). Moreover, conﬂicting reports concerning their
dependence on CIITA have been published for several candi-
dates (60). Therefore, with the exception of the Ii gene, the
RAB4B gene identiﬁed here is the ﬁrst example of a non-
MHC gene that contains a typical S-Y enhancer and is regu-
lated by the same regulatory machinery as MHC-II genes.
RAB4 has a well established function in recycling proteins
and lipids from EE and RE back to the PM. The RAB4A and
RAB4B isoforms co-localize to the same compartments and
are highly homologous, suggesting that they have largely
Figure 7. The RAB4B S-Y module functions as a CIITA and RFX-dependent transcriptional enhancer. (A) Transient transfections were performed with luciferase
reporter gene constructs containing the HLA–DRA regulatory region or hybrid promoters in which the S-Y module from HLA–DRA was replaced with the RAB4B
S-Y sequence in the forward or inverse orientations. A construct containing the basal HLA–DRA promoter lacking the S-Y module (minimal) was used as a
negative control. Constructs were transfected into wt, CIITA-/- and RFX5-/- B cells, and into CIITA-/- and RFX-/- cells complemented with CIITA or RFX5
expression vectors, respectively. Results are expressed as % of the activity of the HLA–DRA S-Y construct in wt cells. (B) Mutations were introduced into the S,
X, X2 and Y sequences of the luciferase construct containing the RAB4B S-Y module. The wt and mutated S, X, X2 and Y sequences are provided. Activities of
the resulting constructs were tested after transfection into wt and CIITA-/- cells. The minimal construct was used as a negative control. Results are expressed as
% of the activity of intact RAB4B construct in wt cells.
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sion by placing it under the control of the MHC-II regulatory
machinery may thus simply be a way of increasing the recy-
cling capacity of APC by raising the total level of RAB4 pro-
tein. However, an alternative possibility is suggested by an
intriguing difference between the two RAB4 isoforms at
amino acid 199. In RAB4A there is a serine (S) at this posi-
tion. Phosphorylation of S199 by the mitotic cdc2 kinase
causes the dissociation of RAB4A from membranes and its
accumulation in the cytoplasm (61,62). This was proposed
to be responsible for the inactivation of RAB4A during mito-
sis. Interestingly, RAB4B has a glutamine (Q) at position
199, a substitution that was shown to prevent the phosphory-
lation and cytoplasmic accumulation of RAB4A. RAB4B is
thus likely to remain active during mitosis. This difference
could underlie a speciﬁc function of RAB4B. Regulating
RAB4B expression by the MHC-II regulatory machinery
may thus be a way of ensuring this speciﬁc function in APC.
Endocytic recycling contributes to antigen presentation
by MHC-II molecules. Cell surface MHC-II molecules can
be internalized by endocytosis, loaded with new peptides in
early endosomes and recycled back to the PM instead of
being targeted for lysosomal degradation (9). Certain MHC-
II restricted peptides do not require extensive processing in
late endosomal compartments and are generated and loaded
onto MHC-II molecules in early endosomes, from which
the MHC-II-peptide complexes are recycled to the cell sur-
face (10–12). This recycling-dependent antigen presentation
pathway is presumably under the control of RAB4. Direct
evidence for a role of RAB4 in antigen presentation has
been provided by studies using a dominant negative mutant
of RAB4A. Transfection of mouse A20 B cells with a domi-
nant negative RAB4A mutant was found to inhibit the pro-
cessing and presentation of certain antigens internalized by
B-cell-receptor (BCR) or Fc-receptor-mediated uptake (13).
Interestingly, we have found that A20 B cells actually express
only RAB4B mRNA (data not shown). The dominant negative
RAB4A mutant must therefore have interfered with the activ-
ity of RAB4B, thereby providing a functional link between
the latter and antigen presentation.
In addition to MHC-II restricted antigen presentation, recy-
cling is known to play key roles in other antigen presentation
processes. Several studies have demonstrated that recycling is
one of the mechanisms that accounts for the ability of DC to
cross-present peptides derived from exogenous antigens in
the context of MHC-I molecules (7,14,15). DC have recently
also been shown to internalize antigens and the recycle them
back to PM for direct presentation to B cells (16). Enhancing
the expression of RAB4B in APC by the MHC-II regulatory
machinery is thus likely to contribute to the efﬁciency of
several different antigen presentation processes.
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